Adalank

Adalank is a synthetic peptide analogue of selank, with targeted chemical alteration.

 

 

SKU: 198803 Kategori:
Del din kærlighed

Adalank is a synthetic peptide analogue of selank, with targeted chemical alteration.

The peptide is designed as a afledt af nootropic drug Selank, with the addition of an acetylated N-terminal function that enhances its adamantane-like sterically-constraining structure.

This modification acts as a powerful synergistic potentiator of the anxiolyticnootropic compound Selank.

It circumvents Selank’s poor blod-hjerne barriere (BBB) penetration, thereby increasing the centralnervesystemet activity of Adalank significantly.

The addition of an acetyl group eliminates the positive charge of the N-terminal free amino group and decreases the net charge of the peptide.

This physicochemical adjustment optimizes the isoelectric point and surface properties of Adalank, reducing non-specific electrostatic interactions.

Som et resultat, the drug molecule crosses the blood–brain barrier more easily and reaches the central nervous system.

Desuden, acetylering protects Adalank from exopeptidase degradation and significantly increases its in vivo half-life.

This provides the advantage of prolonged therapeutic blood levels and reduces frequent dosing.

The inclusion of adamantane creates a stable “conformation core” in the Adalank peptide.

This imparts a fixed spatial orientation to the initially flexible linear peptide, promoting the stereochemical conformation necessary for biological activity even in its unbound state.

This greatly improves Adalank’s ability to cross the blood-brain barrier.

Desuden, Adalank exhibits certain immunomodulatory effects.

Sekvens

ac-thr-lys-pro-arg-pro-gly-pro-Adamantane-nh2

CAS nummer

/

Molekylær formel

C46H75N13O10

Molekylvægt

970.19

Research Of Adalank:

1.Virkningsmekanisme

Efficacy-wise, Adalank’s rigid structure more closely corresponds to the allosteric modulation site of the GABA_A receptor alpha subunit, imparting stronger anxiolytic effects.

Moreover, the adamantane moiety enables hydrophobic interactions in the NMDA-receptor channel area to moderate calcium influx and protect against excitotoxic injury.

This property has the potential for neuroprotection in models of ischemic brain injury and post-traumatic stress disorder (PTSD).

2.Anxiolytic Effects

As an optimized derivative of Selank, Adalank maintains a high-affinity interaction with the benzodiazepine site on the GABA_A receptor α-subunit.

Imidlertid, the N-terminal acetylation and adamantane scaffold shift the binding mode from “flexible induced fit” to “rigid precise docking”.

This enhances GABAergic inhibitory neurotransmission, promoting chloride influx and rapid reduction of activity in hyperactive amygdala-prefrontal cortex neural circuits.

In contrast to benzodiazepines, Adalank shows high receptor subtype selectivity, enabling sustained anxiolytic effects without the sedation, muscle relaxation, or addiction potential associated with traditional drugs.

Its therapeutic index is 3 til 5 times wider, supporting long-term management of generalized anxiety disorder and situational anxiety disorders.

3.Cognitive Enhancement and Memory Improvement

Adalank effectively inhibits the activation of the NF-κB inflammatory pathway and increases BDNF mRNA expression by 50%-80% i hippocampus.

This leads to activation of downstream Akt/CREB signaling pathways, facilitating LTP induction and maintenance.

It significantly improves memory retention in passive avoidance tests, enhances spatial learning in the Morris water maze, and counteracts scopolamine-induced cholinergic damage.

Preclinical data indicate that Adalank reduces working memory errors by 40%-60% and mitigates natural memory decline in aged animals, suggesting applicability in learning disorders, mild cognitive impairment, and age-related memory decline.

4.Neuroprotektive virkninger

The adamantane structure in Adalank mimics the action of memantine, acting as a non-competitive NMDA-receptor antagonist that causes voltage-dependent blockade of open channels and physiological regulation of calcium influx.

It reduces pathological Ca²⁺ influx by 60–70% without impairing physiological synaptic Ca²⁺ signaling, achieving a selective neuroprotective profile without disrupting normal function.

Således, preclinical studies highlight Adalank’s significant translational potential for early intervention in acute stroke, spinal cord injury, og neurodegenerative diseases.

COA

HPLC

MS

(1) Vi vil, C. R.; Hvid, C. M. Sedativ-hypnotiske midler, der påvirker gamma-aminosmørsyrereceptorer: Fokus på Flunitrazepam, Gamma-Hydroxysmørsyre, Phenibut, og Selank. J Clin Pharmacol 2021, 61 Suppl 2, S114-S128. DOI: 10.1002/jcph.1922 From NLM M

(2) Stakkels ting, EN.; Kolomin, T.; Andreeva, L.; Bondarenko, E.; Myasoedov, N.; Slominsky, P.; Shadrina, M. Peptid Selank forbedrer effekten af ​​diazepam til at reducere angst i uforudsigelige kroniske milde stresstilstande hos rotter. Opfør Neurol 2017, 2017, 50910

(3) Stift, L. G.; Nadorova, EN. V.; Antipova, T. EN.; Kruglov, S. V.; Kudrin, V. S.; Durnev, EN. D. Selank, Peptidanalog af Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex

(4) Stift, L. G.; Nadorova, EN. V.; Seredenin, S. B. Selank hæmmer ethanol-induceret hyperbevægelse og manifestation af adfærdssensibilisering hos DBA/2-mus. Bull Exp Biol Med 2016, 162 (1), 56-59. DOI: 10.1007/s10517-016-3544-6 Fra NLM Medline.

(5) Koste, N. V.; Sokolov, O.; Gabaeva, M. V.; Grivennikov, jeg. EN.; Andreeva, L. EN.; Miasoedov, N. F.; Zozulia, EN. EN. [Semax og selank hæmmer de enkephalin-nedbrydende enzymer fra humant serum]]. Bioorg Khim 2001, 27 (3), 180-183. DOI: 10.1023/-en:10113730028

(6) Jeg ved det ikke, G. G.; Teleshova, E. S.; Bochkarev, V. K.; Koschelev, V. V.; Syunyakov, T. S. P.3.036 Ny anxiolytisk Selank: Resultater af fase II kliniske forsøg. Europæisk neuropsykofarmakologi 2005, 15, S159-S160. DOI: 10.1016/s0924-977x(05)80332-3.

(7) Slominsky, P. EN.; Shadrina, M. JEG.; Kolomin, T. EN.; Stavrovskaya, EN. V.; Filatova, E. V.; Andreeva, L. EN.; Illarioshkin, S. N.; Myasoedov, N. F. Peptider semax og selank påvirker adfærden hos rotter med 6-OHDA-induceret PD-lignende parkinsonisme. Dokl Biol Sc

(8) Sollertinskaja, T. N.; Shorokhov, M. V.; Myasoedov, N. F. De cerebrobeskyttende virkninger af Semax og Selank hos primater ved forskellige typer neurose. International Journal of Psychophysiology 2008, 69 (3). DOI: 10.1016/j.ijpsycho.2008.05.356.

Sekvens:

ac-thr-lys-pro-arg-pro-gly-pro-Adamantane-nh2

CAS:

N/A

M.W:

970.19 g/mol

Hjem Søge Whatsapp Tjenester Produkt